VIRTUOZZO
3.6.2021 12:32:08 CEST | Business Wire | Press release
Virtuozzo , a global leader in high-efficiency virtualization and hyperconverged software solutions, has welcomed Mick Bradley as its new Vice President of Global Sales. Mick joins Virtuozzo with over 25 years of sales leadership and management experience in the IT/Software industry, including a strong track record of building successful teams in early and growth-stage organizations while driving sales excellence and partner strategies. Mick will steer Virtuozzo’s global sales team executing the overall sales strategy, including expanding and improving its sales capabilities to support the growth of new customers and its core customer base – Virtuozzo’s network of 450+ service provider partners.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210603005288/en/
Mick’s appointment comes at a pivotal time for Virtuozzo as the Company accelerates growth in new and existing markets. Virtuozzo’s product portfolio is well suited to provide end-to-end cloud enablement for the fast-growing service provider market – both hosting service providers and the Company’s new vertical focus, managed and cloud service providers. Mick’s expertise and leadership will help drive the Company’s strategic vision and accelerate its growth, building upon over 21 years of innovation in the virtualization software business.
Previously Mick served as Senior Vice President & General Manager for EMEA at Arcserve, where he developed and implemented a strategy to move Arcserve from SMB into mid-markets and SME, resulting in significant revenue growth, channel expansion, and a successful transition to cloud service. Prior to this, he held several senior positions, including VP & General Manager for EMEA at Kaminario Inc., EMEA Managing Director at Violin Memory, Senior Director of EMEA Storage Consulting at Hewlett Packard, Chief Operating Officer at CopperEye, and Senior Vice President of Global Services at COPAN Systems.
“We’re thrilled to welcome Mick at such a critical time in Virtuozzo’s evolution. His extensive leadership and sales expertise will help establish Virtuozzo as the global leader in hybrid cloud enablement for the service provider market. Under Mick’s leadership, our sales team is well positioned to continue accelerating our business with a strong global team, solid solution portfolio, and a customer base of 450 service providers worldwide. With his expertise in growing both global and startup sales organizations in the software industry, Mick will bring our business to the next level. We couldn't be more excited," said Alex Fine, CEO, Virtuozzo.
“I’m joining Virtuozzo during an exciting time for both the Company and our partners and look forward to leveraging my experience to help both achieve massive growth. Virtuozzo’s ability to quickly offer cutting-edge cloud services is a game-changer for service providers seeking to differentiate and disrupt today. I am thrilled to be joining Virtuozzo and look forward to great things to come,” remarked Mick Bradley, VP of Global Sales, Virtuozzo.
About Virtuozzo
Virtuozzo is a leading, global provider of hybrid virtualization, storage, and cloud enablement software solutions. The Company's software-defined, hyperconverged self-service platform and resource management capabilities enable hosting and service providers to provide end-customers with public and private cloud services. Virtuozzo is an industry pioneer who developed the first commercially available container technology 21 years ago. The Company provides software solutions and services to over 450 service providers, ISVs, and enterprises worldwide to enable over 500 thousand virtual environments, running mission-critical cloud workloads. A significant force in the open-source community, Virtuozzo sponsors and/or is a contributor to numerous open-source projects including KVM, Docker, OpenStack, OpenVZ, CRIU, and the Linux kernel. Learn more https://go.virtuozzo.com/l/148051/2021-06-02/5kjhgs .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005288/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom